These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34192440)

  • 21. C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
    Uchimoto T; Matsuda T; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Tsuchida S; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
    Target Oncol; 2024 Jul; 19(4):635-644. PubMed ID: 38807017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
    Powles T; Bellmunt J; Comperat E; De Santis M; Huddart R; Loriot Y; Necchi A; Valderrama BP; Ravaud A; Shariat SF; Szabados B; van der Heijden MS; Gillessen S;
    Ann Oncol; 2024 Jun; 35(6):485-490. PubMed ID: 38490358
    [No Abstract]   [Full Text] [Related]  

  • 23. Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinoma.
    Ghatalia P; Plimack ER
    Nat Rev Clin Oncol; 2023 Dec; 20(12):818-819. PubMed ID: 37667009
    [No Abstract]   [Full Text] [Related]  

  • 24. Use of enfortumab vedotin in an HIV-positive patient with urothelial carcinoma.
    Azizi A; Houshyar R; Mar N
    J Oncol Pharm Pract; 2022 Jul; 28(5):1226-1229. PubMed ID: 35043748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Editorial comment from Dr Taguchi to Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study.
    Taguchi S
    Int J Urol; 2024 Apr; 31(4):348. PubMed ID: 38183313
    [No Abstract]   [Full Text] [Related]  

  • 26. Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer.
    Mamtani R; Tsingas K; Parikh RB; Elsouda D; Mucha L; Fuldeore R; Hubbard RA
    Urol Oncol; 2024 Jun; 42(6):177.e1-177.e4. PubMed ID: 38503592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The biology and rationale of targeting nectin-4 in urothelial carcinoma.
    Heath EI; Rosenberg JE
    Nat Rev Urol; 2021 Feb; 18(2):93-103. PubMed ID: 33239713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma.
    Hirotsu KE; Rana J; Wang JY; Raghavan SS; Rieger KE; Srinivas S; Fan AC; Kwong BY; Novoa RA; Zaba LC
    J Am Acad Dermatol; 2021 Dec; 85(6):1610-1611. PubMed ID: 33301805
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors.
    Tang M; Garg A; Bonate PL; Rosenberg JE; Matsangou M; Kadokura T; Yamada A; Choules M; Pavese J; Nagata M; Tenmizu D; Koibuchi A; Heo N; Wang L; Wojtkowski T; Hanley WD; Poondru S
    Clin Pharmacokinet; 2024 Apr; 63(4):423-438. PubMed ID: 38609704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Central Nervous System Disease Progression Among Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Case Series.
    Shipp C; Jindal T; Chou J; Friedlander TW; Koshkin VS; Kumar V
    Clin Genitourin Cancer; 2024 Apr; 22(2):315-321. PubMed ID: 38114390
    [No Abstract]   [Full Text] [Related]  

  • 31. Biomarkers of Response to Anti-NECTIN4 Antibody-Drug Conjugate Enfortumab Vedotin in Urothelial Cancer.
    Klümper N; Eckstein M
    Eur Urol Focus; 2024 Mar; 10(2):224-226. PubMed ID: 38631991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan.
    Hara T; Matsushita Y; Harada K; Fujimoto N; Fujisawa M; Miyake H
    Int J Urol; 2024 Jun; 31(6):696-698. PubMed ID: 38424707
    [No Abstract]   [Full Text] [Related]  

  • 33. Enfortumab Vedotin: Nursing Perspectives on the Management of Adverse Events in Patients With Locally Advanced or Metastatic Urothelial Carcinoma.
    Pace A; Brower B; Conway D; Leis D
    Clin J Oncol Nurs; 2021 Apr; 25(2):E1-E9. PubMed ID: 33739346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enfortumab vedotin - next game-changer in urothelial cancer.
    Maas M; Stühler V; Walz S; Stenzl A; Bedke J
    Expert Opin Biol Ther; 2021 Jul; 21(7):801-809. PubMed ID: 33325754
    [No Abstract]   [Full Text] [Related]  

  • 35. Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date.
    Moussa M; Papatsoris A; Abou Chakra M; Dellis A
    Drug Des Devel Ther; 2021; 15():453-462. PubMed ID: 33603337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
    Hanna KS
    Drugs; 2020 Jan; 80(1):1-7. PubMed ID: 31823332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
    Powles T; Rosenberg JE; Sonpavde GP; Loriot Y; Durán I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Wu C; Campbell M; Matsangou M; Petrylak DP
    N Engl J Med; 2021 Mar; 384(12):1125-1135. PubMed ID: 33577729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Editorial Comment to Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
    Miyata Y; Matsuo T
    Int J Urol; 2022 Jul; 29(7):655. PubMed ID: 35355328
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug extravasation with Enfortumab vedotin.
    Grant CR; de Kouchkovsky D; Kalebasty AR; Mar N
    J Oncol Pharm Pract; 2023 Oct; 29(7):1789-1792. PubMed ID: 37401244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.
    Takahashi S; Uemura M; Kimura T; Kawasaki Y; Takamoto A; Yamaguchi A; Melhem-Bertrandt A; Gartner EM; Inoue T; Akazawa R; Kadokura T; Tanikawa T
    Invest New Drugs; 2020 Aug; 38(4):1056-1066. PubMed ID: 31444589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.